Elon Musk's extraordinary efforts require adequate scrutiny.
Sixteen analysts have cut price targets in the past month, with a smattering of analysts downgrading the stock as well.
Apple's antitrust defense is moot after a narrow court decision on Monday morning.
Uber's IPO move could be a blip on the road to autonomous driving.
Shortseller Andrew Left says Jumia's post IPO stock jump is built on fraud.
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
Aetna's additive effects on CVS's earnings might be front and center, but it isn't fully actualized just yet.
CVS is setting up an anticipated new stock trajectory for investors.
Short-sellers are pointing to a big risk for Tesla investors and an opportunity for traders.
Alphabet is awaiting word today on whether the U.S. Supreme Court will hear its appeal of a $9 billion copyright lawsuit filed by tech rival Oracle Corp.